Purchase this article with an account.
T. Akaishi, N. Ishida, A. Shimazaki; Ocular Hypotensive Effects of Anti–Glaucoma Agents in Mice . Invest. Ophthalmol. Vis. Sci. 2006;47(13):422.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the ocular hypotensive effects produced by topical application of anti–glaucoma agents in mice.
Male ddY mice were housed under a 12–hour light–dark cycle (lights on: 7 am; lights off: 7 pm). With mice under general anesthesia, a microneedle method was used to measure intraocular pressure (IOP). The reduction of IOP was evaluated by the difference between treated and nontreated eyes in the same mouse. Three µL of 0.0015% tafluprost, 0.005% latanoprost, 0.5% timolol maleate, 0.1% dipivefrin hydrochloride, 2% pilocarpine hydrochloride, 0.01% bunazosin hydrochloride, 0.15% brimonidine tartrate, 0.25% nipradilol, 1% dorzolamide hydrochloride or saline was topically applied once into one eye in each mouse at 7 pm. IOP was measured at just before, 1, 2, 3 and 4 hours after instillation of each drug.
The mean baseline IOP during the experiment was 17.9 ± 0.1 mmHg. The maximal IOP reductions of saline, tafluprost, latanoprost, timolol, dipivefrin, pilocarpine, bunazosin, brimonidine, nipradilol, and dorzolamide were 0.0 ± 0.3 mmHg, 4.2 ± 0.8 mmHg, 3.9 ± 0.7 mmHg, 3.2 ± 0.6 mmHg, 4.3 ± 1.4 mmHg, 2.5 ± 0.6 mmHg, 4.4 ± 0.6 mmHg, 3.7 ± 0.5 mmHg, 1.5 ± 0.7 mmHg, and 1.8 ± 0.5 mmHg, respectively. Concomitant administration of tafluprost and timolol or dorzolamide reduced IOP by 5.7 ± 0.5 mmHg or 5.0 ± 0.4 mmHg, respectively.
All ocular hypotensive agents reduced IOP in mice as in human. Especially, tafluprost, latanoprost, dipivefrin and bunazosin showed the potent IOP reduction in mice. These results suggests that mouse is a useful model animal for studying the ocular hypotensive effects of anti–glaucoma agents.
This PDF is available to Subscribers Only